کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2926141 | 1175993 | 2007 | 9 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Beneficios adicionales del tratamiento con candesartán en la insuficiencia cardÃaca. Programa CHARM
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
موضوعات مرتبط
علوم پزشکی و سلامت
پزشکی و دندانپزشکی
کاردیولوژی و پزشکی قلب و عروق
پیش نمایش صفحه اول مقاله

چکیده انگلیسی
The Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program consists of three placebo-controlled clinical trials of candesartan in patients with symptomatic heart failure: two in patients with reduced ventricular function (the CHARM-Added and CHARM-Alternative trials) and one in patients with preserved ventricular function (the CHARM-Preserved trial). In addition, a combined evaluation of the three trials has also been carried out (CHARM-Overall). All trials demonstrated a reduction in cardiovascular morbidity and mortality and/or significant reduction in the number of hospital admissions for heart failure (whether mild or severe), or both, in the groups receiving active treatment. However, the benefit of candesartan overcomes its direct effect in heart failure. It has been demonstrated that candesartan prevents the development of diabetes, atrial fibrillation and myocardial infarction in patients with symptomatic chronic heart failure, what improve, even more the prognosis of these patients. In this manuscript the additional benefits of candesartan in the treatment of heart failure are reviewed.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Hipertensión - Volume 24, Supplement 1, June 2007, Pages 34-42
Journal: Hipertensión - Volume 24, Supplement 1, June 2007, Pages 34-42
نویسندگان
V. Barrios, C. Escobar, A. Calderón,